NEW YORK (GenomeWeb) – IncellDx has partnered with Ann Arbor, Michigan-based Zomedica to identify and enumerate circulating tumor cells from canine cancers using InCellDx’s BioINK liquid biopsy reagent platform.
As part of the agreement, the partners will develop an assay that will combine biomarkers from Zomedica’s canine cancer research programs with IncellDx’s BioINK reagents, which preserve antigen and nucleic acid biomarkers while allowing simultaneous cell cycle determination on single cells captured using the Celsee Genesis instrument.
“IncellDx continues to build on its single-cell technology for both primary tumor and CTCs in blood providing high-parameter detection and bioinformatics prior to or obviating the need for further analysis of captured CTCs,” IncellDx Founder and CEO Bruce Patterson said in a statement.
Additional details of the partnership were not disclosed.
“This interdisciplinary animal and human health collaboration or ‘One Health’ approach is critical to achieving optimal outcomes to diagnose and treat cancer more effectively,” Stephanie Morley, Zomedica’s chief operating officer and VP of product development, said in a statement. [Emphasis added.]
Zomedica previously signed a license and supply agreement with CelSee in 2017 to develop and market the Genesis liquid biopsy platform to be used in the veterinary space as a cancer diagnostic.
